Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 15/20 | 0.54 |
| ▸ | OPRM1 | P35372 | 14/20 | 0.54 |
| ▸ | OPRK1 | P41145 | 13/20 | 0.54 |
| ▸ | OPRD1 | P41143 | 6/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA4 | P22748 | 1/20 | 0.35 |
| ▸ | CA5A | P35218 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.35 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7878565 | 0.86 | CHRNA7 (0.49) | OPRL1OPRM1OPRK1OPRD1SMN1; SMN2 | |
| SCHEMBL7878435 | 0.86 | CHRNA7 (0.49) | OPRL1OPRM1OPRK1OPRD1SMN1; SMN2 | |
| SCHEMBL7886366 | 0.82 | SMN1; SMN2 (0.48) | OPRL1OPRM1OPRK1OPRD1SMN1; SMN2 | |
| SCHEMBL7886369 | 0.82 | SMN1; SMN2 (0.48) | OPRL1OPRM1OPRK1OPRD1SMN1; SMN2 | |
| SCHEMBL7887827 | 0.82 | SMN1; SMN2 (0.48) | OPRL1OPRM1OPRK1OPRD1SMN1; SMN2 | |
| SCHEMBL7014225 | 0.78 | SMN1; SMN2 (0.43) | OPRL1OPRM1OPRK1OPRD1SMN1; SMN2 | |
| SCHEMBL7016091 | 0.76 | OPRL1 (0.51) | OPRL1OPRM1OPRK1OPRD1SMN1; SMN2 | |
| SCHEMBL7889657 | 0.75 | OPRL1 (0.49) | OPRL1OPRM1OPRK1OPRD1SMN1; SMN2 | |
| SCHEMBL7885705 | 0.75 | OPRL1 (0.49) | OPRL1OPRM1OPRK1OPRD1SMN1; SMN2 | |
| SCHEMBL7015691 | 0.75 | OPRL1 (0.49) | OPRL1OPRM1OPRK1OPRD1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6642247-B2 | Treting anxiety, stress, depression, trauma, Alzheimer's mediated memory loss, epilepsy, arterial blood pressure disorders, obesity, acute pain, chronic pain, Na+ excretion, control of water balance, and symptoms associated with drug | HOFFMAN-LA ROCHE INC. | 2003-11-04 | — | — | US | disclosed |
| US-20030176701-A1 | DI-OR TRIAZA-SPIRO [4,5] DECANE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-09-18 | — | — | US | disclosed |
| EP-0963985-B1 | Di-or triaza-spiro(4,5)decane derivatives | HOFFMANN LA ROCHE (CH) | 2003-03-12 | — | — | EP | disclosed |
| EP-0963985-A2 | Di-or triaza-spiro(4,5)decane derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1999-12-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176701-A1 | DI-OR TRIAZA-SPIRO [4,5] DECANE DERIVATIVES | NPY4R, NPY1R, OXER1 | OPRL1 36/4885OPRM1 152/4885OPRK1 106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.